Optimal cost-effective designs of phase ii proof of concept trials and associated go-no go decisions

Journal of Biopharmaceutical Statistics

Volumn 19, Issue 3, 2009, Pages 424-436

  Chen, Cong ^a   Beckman, Robert A ^a,b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b INSTITUTE FOR ADVANCED STUDY   (United States)

Author keywords

Confirmation trial; Oncology; Power; Treatment effect; Type I error rate

Indexed keywords

ARTICLE; CANCER THERAPY; CLINICAL EFFECTIVENESS; CLINICAL STUDY; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG DESIGN; DRUG INDUSTRY; DRUG MANUFACTURE; ERROR; HUMAN; METHODOLOGY; PRIORITY JOURNAL; PROBABILITY; PROOF OF CONCEPT; PUBLICATION; SAMPLE SIZE; COST BENEFIT ANALYSIS; DECISION THEORY; ECONOMICS; PHASE 2 CLINICAL TRIAL; STANDARD; STATISTICS;

CLINICAL TRIALS, PHASE II AS TOPIC; COST-BENEFIT ANALYSIS; DECISION THEORY; RESEARCH DESIGN;

EID: 67651027168     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543400902800478     Document Type: Article

References (11)

1. Estey, E. H., Thall, P. F. (2003). New designs for Phase 2 clinical trials. Blood 102:442-448.
2. Halpern, J., Brown, B. W., Hornberger, J. (2001). The sample size for a clinical trial: A Bayesian-decision theoretic approach. Stat. Med. 20:841-858.
3. Korn, E. L., Arbuck, S. G., Pluda, J. M. et al. (2001). Clinical trial designs for cytostatic agents: Are new approaches needed? J. Clin. Oncol. 19:265-272, 3154-3160 (correspondence)
4. O'Hagan, A., Stevens, J. W. (2001). Bayesian assessment of sample size for clinical trials of cost-effectiveness. Med. Decision Making 21:219-230.
5. R Development Core Team. (2005). R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing. ISBN 3-900051-07-0, URL http://www.R-project.org.
6. Rubinstein, L. V., Korn, E. L., Freidlin, B. et al. (2005). Design issues of randomized Phase II trials and a proposal for Phase II screening trials. J. Clin. Oncol. 23:7199-7206.
7. Sargent, D. J., Goldberg, R. M. (2001). A flexible design for multiple armed screening trials. Stat. Med. 20:1051-1060.
8. Simon, R. (1989). Optimal two-stage designs for Phase II clinical trials. Contr. Clin. Trials 10:1-10.
9. Simon, R. M., Steinberg, S. M., Hamilton, M. et al. (2001). Clinical trial designs for the early clinical development of therapeutic cancer vaccines. J. Clin. Oncol. 19:1848-1854.
10. Stallard, N., Thall, P. F. (2001). Decision-theoretic designs for pre-Phase II screening trials in oncology. Biometrics 57:1089-1095.
11. Yin, Y. (2002). Sample size calculations for a proof of concept study. J. Biopharm. Stat. 12:267-276.